SCHEMBL2118481

SCHEMBL2118481

COc1ccc(S(=O)(=O)Nc2cc(-c3cccs3)ccc2C)cn1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 7/20 0.49
KDM4E B2RXH2 3/20 0.47
POLB P06746 1/20 0.47
ALDH1A1 P00352 3/20 0.45
MAPT P10636 3/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ACLY P53396 3/20 0.44
KIT P10721 1/20 0.44
PTGES2 Q9H7Z7 1/20 0.44
PIK3CA P42336 2/20 0.43
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PIK3CD O00329 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
CCR2 P41597 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119636 0.87 GHSR (0.52) GHSRKDM4EPOLBALDH1A1MAPT
SCHEMBL2119338 0.85 GHSR (0.47) GHSRKDM4EALDH1A1MAPTMEN1
SCHEMBL2119994 0.85 GHSR (0.47) GHSRKDM4EALDH1A1MAPTMEN1
SCHEMBL2116804 0.85 KIT (0.46) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL2117734 0.83 KIT (0.44) KDM4EPOLBALDH1A1MAPTMEN1
SCHEMBL2119816 0.82 KIT (0.45) GHSRKDM4EPOLBALDH1A1MAPT
SCHEMBL2121927 0.81 KDM4E (0.45) GHSRKDM4EPOLBALDH1A1MAPT
SCHEMBL2118227 0.81 GHSR (0.47) GHSRKDM4EALDH1A1MAPTMEN1
SCHEMBL2117478 0.81 GHSR (0.50) GHSRKDM4EPOLBALDH1A1MAPT
SCHEMBL2119666 0.80 GHSR (0.56) GHSRKDM4EPOLBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 GHSR 1390/4885KDM4E 191/4885POLB 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.